20537/CRUK_/Cancer Research UK/United Kingdom[Grants and Funding] - Search Results

Year	Number of Results
2014	2
2015	2
2016	3
2017	4
2018	3
2019	3
2020	8
2021	2
2022	4
2023	3
2024	1

1

Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity.

Kennedy PT, Saulters EL, Duckworth AD, Lim YJ, Woolley JF, Slupsky JR, Cragg MS, Ward FJ, Dahal LN. Kennedy PT, et al. Mol Ther. 2024 Feb 7;32(2):457-468. doi: 10.1016/j.ymthe.2023.11.028. Epub 2023 Dec 5. Mol Ther. 2024. PMID: 38053333 Free article.

2

Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives.

Dadas O, Ertay A, Cragg MS. Dadas O, et al. Front Immunol. 2023 Apr 25;14:1147467. doi: 10.3389/fimmu.2023.1147467. eCollection 2023. Front Immunol. 2023. PMID: 37180119 Free PMC article. Review.

3

Reducing affinity as a strategy to boost immunomodulatory antibody agonism.

Yu X, Orr CM, Chan HTC, James S, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, Cox KL, Essex JW, Tews I, Glennie MJ, Cragg MS. Yu X, et al. Nature. 2023 Feb;614(7948):539-547. doi: 10.1038/s41586-022-05673-2. Epub 2023 Feb 1. Nature. 2023. PMID: 36725933

4

Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma.

Webb ER, Moreno-Vincente J, Easton A, Lanati S, Taylor M, James S, Williams EL, English V, Penfold C, Beers SA, Gray JC. Webb ER, et al. iScience. 2022 Aug 23;25(9):104995. doi: 10.1016/j.isci.2022.104995. eCollection 2022 Sep 16. iScience. 2022. PMID: 36097618 Free PMC article.

5

Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility.

Orr CM, Fisher H, Yu X, Chan CH, Gao Y, Duriez PJ, Booth SG, Elliott I, Inzhelevskaya T, Mockridge I, Penfold CA, Wagner A, Glennie MJ, White AL, Essex JW, Pearson AR, Cragg MS, Tews I. Orr CM, et al. Sci Immunol. 2022 Jul 15;7(73):eabm3723. doi: 10.1126/sciimmunol.abm3723. Epub 2022 Jul 8. Sci Immunol. 2022. PMID: 35857577

6

Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering.

Heckel F, Turaj AH, Fisher H, Chan HTC, Marshall MJE, Dadas O, Penfold CA, Inzhelevskaya T, Mockridge CI, Alvarado D, Tews I, Keler T, Beers SA, Cragg MS, Lim SH. Heckel F, et al. Commun Biol. 2022 Mar 14;5(1):229. doi: 10.1038/s42003-022-03182-6. Commun Biol. 2022. PMID: 35288635 Free PMC article.

7

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.

Moreno-Vicente J, Willoughby JE, Taylor MC, Booth SG, English VL, Williams EL, Penfold CA, Mockridge CI, Inzhelevskaya T, Kim J, Chan HTC, Cragg MS, Gray JC, Beers SA. Moreno-Vicente J, et al. J Immunother Cancer. 2022 Jan;10(1):e003735. doi: 10.1136/jitc-2021-003735. J Immunother Cancer. 2022. PMID: 35017153 Free PMC article.

8

TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.

Yu X, James S, Felce JH, Kellermayer B, Johnston DA, Chan HTC, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, Watanabe Y, Crispin M, French RR, Duriez PJ, Douglas LR, Glennie MJ, Cragg MS. Yu X, et al. Commun Biol. 2021 Jun 23;4(1):772. doi: 10.1038/s42003-021-02309-5. Commun Biol. 2021. PMID: 34162985 Free PMC article.

9

Domain binding and isotype dictate the activity of anti-human OX40 antibodies.

Griffiths J, Hussain K, Smith HL, Sanders T, Cox KL, Semmrich M, Mårtensson L, Kim J, Inzhelevskaya T, Penfold CA, Tutt AL, Mockridge CI, Chan HC, English V, French RF, Teige I, Al-Shamkhani A, Glennie MJ, Frendeus BL, Willoughby JE, Cragg MS. Griffiths J, et al. J Immunother Cancer. 2020 Dec;8(2):e001557. doi: 10.1136/jitc-2020-001557. J Immunother Cancer. 2020. PMID: 33428585 Free PMC article.

10

Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies.

Preillon J, Cuende J, Rabolli V, Garnero L, Mercier M, Wald N, Pappalardo A, Denies S, Jamart D, Michaux AC, Pirson R, Pitard V, Bagot M, Prasad S, Houthuys E, Brouwer M, Marillier R, Lambolez F, Marchante JR, Nyawouame F, Carter MJ, Baron-Bodo V, Marie-Cardine A, Cragg M, Déchanet-Merville J, Driessens G, Hoofd C. Preillon J, et al. Mol Cancer Ther. 2021 Jan;20(1):121-131. doi: 10.1158/1535-7163.MCT-20-0464. Epub 2020 Dec 4. Mol Cancer Ther. 2021. PMID: 33277440

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

31 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year